Alternatively, total atherogenic cholesterol content (non-HDL-C) or total number of atherogenic particles (apo B) can be obtained from non-fasting samples offering a more comprehensive measure of atherogenic risk, especially when apo B and non-HDL-C are discordant with LDL-C such as in conditions associated with insulin resistance, such as diabetes, obesity and high TG. This evidence concerns the gene APOB and Obesity.